Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Chronic graft-versus-host disease: where do we go from here?

Bone Marrow Transplantation volume 33, pages 569–577 (2004)Cite this article

Summary:

Chronic graft-versus-host disease (GvHD) remains a significant cause of late morbidity and mortality following allogeneic stem cell transplantation. However, patients with chronic GvHD are very heterogeneous, making evaluation and treatment difficult. Corticosteroids remain the most effective primary treatment of this condition. Randomized trials have not confirmed the beneficial effect of additional cyclosporine, even in patients with higher risk features. For patients failing initial therapy, no standard therapy is available. A plethora of drugs have been reported to have activity and promise in this disease. However, the majority of reports are small retrospective studies, with few prospective trials. The marked variability in the reported response rates for many of these novel agents highlights a number of problems in the evaluation and management of chronic GvHD. In addition to the heterogeneity of patients, there are no uniform definitions for treatment failure, prognostic criteria to stratify patients according to risk, or to evaluate response to treatment, which in many cases is largely subjective. The challenge ahead is to develop more uniform criteria for defining many of these important variables, which is likely to lead to the design of better prospective clinical trials to improve the outcome of patients with this condition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Socie G, Stone JV, Wingard JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14–21.

    CAS  Google Scholar 

  2. Kiss TL, Abdolell M, Jamal N et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20: 2334–2343.

    CAS  Google Scholar 

  3. Lee JH, Choi SJ, Kim S et al. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. Br J Haematol 2003; 122: 637–644.

    Google Scholar 

  4. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.

    CAS  Google Scholar 

  5. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  Google Scholar 

  6. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565–1577.

    CAS  Google Scholar 

  7. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    CAS  Google Scholar 

  8. Collins Jr RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Google Scholar 

  9. Ratanatharathorn V, Ayash L, Lazarus HM et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001; 28: 121–129.

    CAS  Google Scholar 

  10. Vogelsang GB . How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196–1201.

    CAS  Google Scholar 

  11. Graze PR, Gale RP . Chronic graft versus host disease: a syndrome of disordered immunity. Am J Med 1979; 66: 611–620.

    CAS  Google Scholar 

  12. Sullivan KM, Mori M, Sanders J et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl. 1): 127–134.

    Google Scholar 

  13. Atkinson K, Horowitz MM, Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464.

    CAS  Google Scholar 

  14. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276.

    CAS  Google Scholar 

  15. Snover DC . Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms. Hum Pathol 1984; 15: 202–205.

    CAS  Google Scholar 

  16. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    CAS  Google Scholar 

  17. Atkinson K, Horowitz MM, Gale RP et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 247–254.

    CAS  Google Scholar 

  18. Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.

    CAS  Google Scholar 

  19. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–554.

    CAS  Google Scholar 

  20. Wingard JR, Piantadosi S, Vogelsang GB et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 74: 1428–1435.

    CAS  Google Scholar 

  21. Arora M, Burns LJ, Davies SM et al. Chronic graft versus host disease: a prospective cohort study. Blood 2001; 98: 1667a.

    Google Scholar 

  22. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    CAS  Google Scholar 

  23. Pavletic SZ, Tarantolo S, Lynch JC et al. Chronic graft-versus-host disease after allogeneic blood stem cell or bone marrow transplantation: factors determining the onset and survival. Proc Am Soc Clin Oncol 1999; 18: 201a.

    Google Scholar 

  24. Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.

    CAS  Google Scholar 

  25. Akpek G, Zahurak ML, Piantadosi S et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219–1226.

    CAS  Google Scholar 

  26. Akpek G, Lee SJ, Flowers ME et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102: 802–809.

    CAS  Google Scholar 

  27. Lazarus HM, Vogelsang GB, Rowe JM . Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997; 19: 577–600.

    CAS  Google Scholar 

  28. Kanamaru A, Takemoto Y, Kakishita E et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995; 15: 885–889.

    CAS  Google Scholar 

  29. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.

    CAS  Google Scholar 

  30. Ringden O, Labopin M, Gluckman E et al. Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Transplant Proc 1997; 29: 733–734.

    CAS  Google Scholar 

  31. Flowers ME, Kansu E, Sullivan KM . Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13: 1091–1112.

    CAS  Google Scholar 

  32. Jacobsohn DA, Montross S, Anders V, Vogelsang GB . Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant 2001; 28: 1047–1051.

    CAS  Google Scholar 

  33. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72: 555–561.

    CAS  Google Scholar 

  34. Koc S, Leisenring W, Flowers ME et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100: 48–51.

    CAS  Google Scholar 

  35. Carnevale-Schianca F, Martin P et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 613–620.

    CAS  Google Scholar 

  36. Nagler A, Menachem Y, Ilan Y . Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment. J Hematother Stem Cell Res 2001; 10: 411–417.

    CAS  Google Scholar 

  37. Stratta RJ . Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group. Transplant Proc 1997; 29: 654–655.

    CAS  Google Scholar 

  38. Mookerjee B, Altomonte V, Vogelsang G . Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517–520.

    CAS  Google Scholar 

  39. Baudard M, Vincent A, Moreau P et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 30: 287–295.

    CAS  Google Scholar 

  40. Busca A, Saroglia EM, Lanino E et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000; 25: 1067–1071.

    CAS  Google Scholar 

  41. Busca A, Locatelli F, Marmont F et al. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica 2003; 88: 837–839.

    Google Scholar 

  42. Singhal S, Mehta J . Thalidomide in cancer: potential uses and limitations. BioDrugs 2001; 15: 163–172.

    CAS  Google Scholar 

  43. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055–1058.

    CAS  Google Scholar 

  44. Rovelli A, Arrigo C, Nesi F et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998; 21: 577–581.

    CAS  Google Scholar 

  45. van de Poel MH, Pasman PC, Schouten HC . The use of thalidomide in chronic refractory graft versus host disease. Neth J Med 2001; 59: 45–49.

    CAS  Google Scholar 

  46. Browne PV, Weisdorf DJ, DeFor T et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000; 26: 865–869.

    CAS  Google Scholar 

  47. Kulkarni S, Powles R, Sirohi B et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003; 32: 165–170.

    CAS  Google Scholar 

  48. Parker PM, Chao N, Nademanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604–3609.

    CAS  Google Scholar 

  49. Koc S, Leisenring W, Flowers ME et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000; 96: 3995–4006.

    CAS  Google Scholar 

  50. Olson NY, Lindsley CB . Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989; 16: 1545–1547.

    CAS  Google Scholar 

  51. Ziegler HK, Unanue ER . Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 1982; 79: 175–178.

    CAS  Google Scholar 

  52. Ertel W, Morrison MH, Ayala A, Chaudry IH . Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 1991; 78: 1781–1788.

    CAS  Google Scholar 

  53. Gilman AL, Beams F, Tefft M, Mazumder A . The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplant 1996; 17: 1069–1075.

    CAS  Google Scholar 

  54. Schultz KR, Bader S, Nelson D et al. Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist? Transplantation 1997; 64: 1055–1065.

    CAS  Google Scholar 

  55. Gilman AL, Chan KW, Mogul A et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 327–334.

    CAS  Google Scholar 

  56. Crovato F, Levi L . Clofazimine in the treatment of annular lupus erythematosus. Arch Dermatol 1981; 117: 249–250.

    CAS  Google Scholar 

  57. Mensing H . Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. Dermatologica 1988; 177: 232–236.

    CAS  Google Scholar 

  58. Lee SJ, Wegner SA, McGarigle CJ et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997; 89: 2298–2302.

    CAS  Google Scholar 

  59. Dreno B, Celerier P, Litoux P . Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 1993; 89 (Suppl. 1): 28–32.

    Google Scholar 

  60. Marcellus DC, Altomonte VL, Farmer ER et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999; 93: 66–70.

    CAS  Google Scholar 

  61. Enk CD, Elad S, Vexler A et al. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998; 22: 1179–1183.

    CAS  Google Scholar 

  62. Eppinger T, Ehninger G, Steinert M et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807–811.

    CAS  Google Scholar 

  63. Atkinson K, Weller P, Ryman W, Biggs J . PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1: 227–236.

    CAS  Google Scholar 

  64. Vogelsang GB, Wolff D, Altomonte V et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 1061–1067.

    CAS  Google Scholar 

  65. Redding SW, Callander NS, Haveman CW, Leonard DL . Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86: 183–187.

    CAS  Google Scholar 

  66. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.

    CAS  Google Scholar 

  67. Messina C, Locatelli F, Lanino E et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118–127.

    CAS  Google Scholar 

  68. Seaton ED, Szydlo RM, Kanfer E et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217–1223.

    CAS  Google Scholar 

  69. DiVenuti G, Miller DF, Sprague K et al. Phopheresis as a treatment for chronic graft-vs-host disease after allogeneic bone marrow transplantation. Blood 2002; 100: 846a.

    Google Scholar 

  70. French LE, Alcindor T, Shapiro M et al. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 2002; 30: 509–515.

    CAS  Google Scholar 

  71. Gorgun G, Miller KB, Foss FM . Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100: 941–947.

    CAS  Google Scholar 

  72. Steis RG, Urba WJ, Kopp WC et al. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients. J Natl Cancer Inst 1991; 83: 1678–1679.

    CAS  Google Scholar 

  73. Kraut EH, Neff JC, Bouroncle BA et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8: 848–855.

    CAS  Google Scholar 

  74. Bolanos-Meade J, Jacobsohn DA, Margolis DJ et al. Pentostatin in steroid refractory acute graft versus host disease. Blood 2002; 100: 420a.

    Google Scholar 

  75. Chiang KY, Abhyankar S, Bridges K et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665–667.

    CAS  Google Scholar 

  76. Couriel D, Saliba R, Hicks K et al. TNF-alpha inhibition for the treatment of chronic GVHD. Blood 2002; 100: 847a.

    Google Scholar 

  77. Willenbacher W, Basara N, Blau IW et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820–823.

    CAS  Google Scholar 

  78. Ratanatharathorn V, Ayash L, Reynolds C et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505–511.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Bone Marrow Transplant Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

    S S Farag

Authors
  1. S S Farag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S S Farag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farag, S. Chronic graft-versus-host disease: where do we go from here?. Bone Marrow Transplant 33, 569–577 (2004). https://doi.org/10.1038/sj.bmt.1704410

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704410

Keywords

This article is cited by

Search

Advanced search

Quick links